Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Introduction Teclistamab is the first approved B cell maturation antigen × CD3 bispecific antibody with precision dosing for the treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). We compared the effectiveness of teclistamab in MajesTEC-1 versus real-world physician...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Advances in therapy 2024-02, Vol.41 (2), p.696-715
Hauptverfasser:	Moreau, Philippe, Mateos, María-Victoria, Gonzalez Garcia, Maria Esther, Einsele, Hermann, De Stefano, Valerio, Karlin, Lionel, Lindsey-Hill, Joanne, Besemer, Britta, Vincent, Laure, Kirkpatrick, Suriya, Delforge, Michel, Perrot, Aurore, van de Donk, Niels W. C. J., Pawlyn, Charlotte, Manier, Salomon, Leleu, Xavier, Martinez-Lopez, Joaquin, Ghilotti, Francesca, Diels, Joris, Morano, Raúl, Albrecht, Claire, Strulev, Vadim, Haddad, Imène, Pei, Lixia, Kobos, Rachel, Smit, Jennifer, Slavcev, Mary, Marshall, Alexander, Weisel, Katja
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiology Endocrinology Internal Medicine Medicine Medicine & Public Health Oncology Original Research Pharmacology/Toxicology Rheumatology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!